Non-coding RNAs as modulators of the cardiac fibroblast phenotype

Journal of Molecular and Cellular Cardiology

Volumn 92, Issue , 2016, Pages 75-81

  Piccoli, Maria Teresa ^a   Bär, Christian ^a   Thum, Thomas ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Cardiac fibrosis; Heart failure; Long noncoding RNA; MicroRNA

Indexed keywords

LONG UNTRANSLATED RNA; MICRORNA; UNTRANSLATED RNA;

AORTA STENOSIS; APOPTOSIS; CELL FUNCTION; EXTRACELLULAR MATRIX; GENOME; HEART ARRHYTHMIA; HEART FAILURE; HEART FIBROBLAST; HEART INFARCTION; HEART MUSCLE CELL; HEART MUSCLE FIBROSIS; HUMAN; HYPERTENSION; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; REVIEW; ANIMAL; CARDIAC MUSCLE; CARDIOMEGALY; FIBROBLAST; GENETICS; METABOLISM; PATHOLOGY;

ANIMALS; CARDIOMEGALY; FIBROBLASTS; HUMANS; MYOCARDIUM; PHENOTYPE; RNA, LONG NONCODING;

EID: 84957586420     PISSN: 00222828     EISSN: 10958584     Source Type: Journal    
DOI: 10.1016/j.yjmcc.2015.12.023     Document Type: Review

References (97)

1. Camelliti P., Borg T.K., Kohl P. Structural and functional characterisation of cardiac fibroblasts. Cardiovasc. Res. 2005, 65:40-51.
2. Vliegen H.W., van der Laarse A., Cornelisse C.J., Eulderink F. Myocardial changes in pressure overload-induced left ventricular hypertrophy. A study on tissue composition, polyploidization and multinucleation. Eur. Heart J. 1991, 12:488-494.
3. Banerjee I., Fuseler J.W., Price R.L., Borg T.K., Baudino T.A. Determination of cell types and numbers during cardiac development in the neonatal and adult rat and mouse. Am. J. Physiol. Heart Circ. Physiol. 2007, 293:H1883-H1891.
4. Kong P., Christia P., Frangogiannis N.G. The pathogenesis of cardiac fibrosis. Cell. Mol. Life Sci. 2014, 71:549-574.
5. Weber K.T., Sun Y., Bhattacharya S.K., Ahokas R.A., Gerling I.C. Myofibroblast-mediated mechanisms of pathological remodelling of the heart. Nat. Rev. Cardiol. 2013, 10:15-26.
6. Weber K.T. Cardiac interstitium in health and disease: the fibrillar collagen network. J. Am. Coll. Cardiol. 1989, 13:1637-1652.
7. Daskalopoulos E.P., Janssen B.J., Blankesteijn W.M. Myofibroblasts in the infarct area: concepts and challenges. Microsc. Microanal. 2012, 18:35-49.
8. Tomasek J.J., Gabbiani G., Hinz B., Chaponnier C., Brown R.A. Myofibroblasts and mechano-regulation of connective tissue remodelling. Nat. Rev. Mol. Cell Biol. 2002, 3:349-363.
9. Shephard P., Martin G., Smola-Hess S., Brunner G., Krieg T., Smola H. Myofibroblast differentiation is induced in keratinocyte-fibroblast co-cultures and is antagonistically regulated by endogenous transforming growth factor-beta and interleukin-1. Am. J. Pathol. 2004, 164:2055-2066.
10. van Nieuwenhoven F.A., Turner N.A. The role of cardiac fibroblasts in the transition from inflammation to fibrosis following myocardial infarction. Vasc. Pharmacol. 2013, 58:182-188.
11. Moore-Morris T., Guimaraes-Camboa N., Banerjee I., Zambon A.C., Kisseleva T., Velayoudon A., et al. Resident fibroblast lineages mediate pressure overload-induced cardiac fibrosis. J. Clin. Invest. 2014, 124:2921-2934.
12. Desmouliere A., Redard M., Darby I., Gabbiani G. Apoptosis mediates the decrease in cellularity during the transition between granulation tissue and scar. Am. J. Pathol. 1995, 146:56-66.
13. Willems I.E., Havenith M.G., De Mey J.G., Daemen M.J. The alpha-smooth muscle actin-positive cells in healing human myocardial scars. Am. J. Pathol. 1994, 145:868-875.
14. Li Y., Takemura G., Kosai K., Takahashi T., Okada H., Miyata S., et al. Critical roles for the Fas/Fas ligand system in postinfarction ventricular remodeling and heart failure. Circ. Res. 2004, 95:627-636.
15. Zhang W., Xu X., Kao R., Mele T., Kvietys P., Martin C.M., et al. Cardiac fibroblasts contribute to myocardial dysfunction in mice with sepsis: the role of NLRP3 inflammasome activation. PLoS One 2014, 9.
16. Lindner D., Zietsch C., Tank J., Sossalla S., Fluschnik N., Hinrichs S., et al. Cardiac fibroblasts support cardiac inflammation in heart failure. Basic Res. Cardiol. 2014, 109:428.
17. Sun Y., Weber K.T. Infarct scar: a dynamic tissue. Cardiovasc. Res. 2000, 46:250-256.
18. Zannad F., Dousset B., Alla F. Treatment of congestive heart failure: interfering the aldosterone-cardiac extracellular matrix relationship. Hypertension 2001, 38:1227-1232.
19. Zhao J., Trew M.L., Legrice I.J., Smaill B.H., Pullan A.J. A tissue-specific model of reentry in the right atrial appendage. J. Cardiovasc. Electrophysiol. 2009, 20:675-684.
20. Oren R.V., Clancy C.E. Determinants of heterogeneity, excitation and conduction in the sinoatrial node: a model study. PLoS Comput. Biol. 2010, 6.
21. de Jong S., van Veen T.A., van Rijen H.V., de Bakker J.M. Fibrosis and cardiac arrhythmias. J. Cardiovasc. Pharmacol. 2011, 57:630-638.
22. Camelliti P., Green C.R., Kohl P. Structural and functional coupling of cardiac myocytes and fibroblasts. Adv. Cardiol. 2006, 42:132-149.
23. Zhang P., Su J., Mende U. Cross talk between cardiac myocytes and fibroblasts: from multiscale investigative approaches to mechanisms and functional consequences. Am. J. Physiol. Heart Circ. Physiol. 2012, 303:H1385-H1396.
24. Thompson S.A., Copeland C.R., Reich D.H., Tung L. Mechanical coupling between myofibroblasts and cardiomyocytes slows electric conduction in fibrotic cell monolayers. Circulation 2011, 123:2083-2093.
25. Krenning G., Zeisberg E.M., Kalluri R. The origin of fibroblasts and mechanism of cardiac fibrosis. J. Cell. Physiol. 2010, 225:631-637.
26. Ali S.R., Ranjbarvaziri S., Talkhabi M., Zhao P., Subat A., Hojjat A., et al. Developmental heterogeneity of cardiac fibroblasts does not predict pathological proliferation and activation. Circ. Res. 2014, 115:625-635.
27. Ieda M., Tsuchihashi T., Ivey K.N., Ross R.S., Hong T.T., Shaw R.M., et al. Cardiac fibroblasts regulate myocardial proliferation through beta1 integrin signaling. Dev. Cell 2009, 16:233-244.
28. Bang C., Batkai S., Dangwal S., Gupta S.K., Foinquinos A., Holzmann A., et al. Cardiac fibroblast-derived microRNA passenger strand-enriched exosomes mediate cardiomyocyte hypertrophy. J. Clin. Invest. 2014, 124:2136-2146.
29. Driesen R.B., Nagaraju C.K., Abi-Char J., Coenen T., Lijnen P.J., Fagard R.H., et al. Reversible and irreversible differentiation of cardiac fibroblasts. Cardiovasc. Res. 2014, 101:411-422.
30. Liew C.C., Dzau V.J. Molecular genetics and genomics of heart failure. Nat. Rev. Genet. 2004, 5:811-825.
31. Fyhrquist F., Saijonmaa O., Strandberg T. The roles of senescence and telomere shortening in cardiovascular disease. Nat. Rev. Cardiol. 2013, 10:274-283.
32. Djebali S., Davis C.A., Merkel A., Dobin A., Lassmann T., Mortazavi A., et al. Landscape of transcription in human cells. Nature 2012, 489:101-108.
33. Thum T., Condorelli G. Long noncoding RNAs and MicroRNAs in cardiovascular pathophysiology. Circ. Res. 2015, 116:751-762.
34. Rizki G., Boyer L.A. Lncing epigenetic control of transcription to cardiovascular development and disease. Circ. Res. 2015, 117:192-206.
35. Fabian M.R., Sonenberg N., Filipowicz W. Regulation of mRNA translation and stability by microRNAs. Annu. Rev. Biochem. 2010, 79:351-379.
36. Kozomara A., Griffiths-Jones S. miRBase: integrating microRNA annotation and deep-sequencing data. Nucleic Acids Res. 2011, 39:D152-D157.
37. Jiang Q., Wang Y., Hao Y., Juan L., Teng M., Zhang X., et al. miR2Disease: a manually curated database for microRNA deregulation in human disease. Nucleic Acids Res. 2009, 37:D98-104.
38. Small E.M., Olson E.N. Pervasive roles of microRNAs in cardiovascular biology. Nature 2011, 469:336-342.
39. Thum T. Noncoding RNAs and myocardial fibrosis. Nat. Rev. Cardiol. 2014, 11:655-663.
40. Lewis B.P., Burge C.B., Bartel D.P. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell 2005, 120:15-20.
41. Friedman R.C., Farh K.K., Burge C.B., Bartel D.P. Most mammalian mRNAs are conserved targets of microRNAs. Genome Res. 2009, 19:92-105.
42. Rao P.K., Toyama Y., Chiang H.R., Gupta S., Bauer M., Medvid R., et al. Loss of cardiac microRNA-mediated regulation leads to dilated cardiomyopathy and heart failure. Circ. Res. 2009, 105:585-594.
43. Chen J.F., Murchison E.P., Tang R., Callis T.E., Tatsuguchi M., Deng Z., et al. Targeted deletion of Dicer in the heart leads to dilated cardiomyopathy and heart failure. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:2111-2116.
44. da Costa Martins P.A., Bourajjaj M., Gladka M., Kortland M., van Oort R.J., Pinto Y.M., et al. Conditional dicer gene deletion in the postnatal myocardium provokes spontaneous cardiac remodeling. Circulation 2008, 118:1567-1576.
45. Melman Y.F., Shah R., Das S. MicroRNAs in heart failure: is the picture becoming less miRky?. Circ. Heart Fail. 2014, 7:203-214.
46. Thum T., Gross C., Fiedler J., Fischer T., Kissler S., Bussen M., et al. MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts. Nature 2008, 456:980-984.
47. van Rooij E., Sutherland L.B., Liu N., Williams A.H., McAnally J., Gerard R.D., et al. A signature pattern of stress-responsive microRNAs that can evoke cardiac hypertrophy and heart failure. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:18255-18260.
48. Roy S., Khanna S., Hussain S.R., Biswas S., Azad A., Rink C., et al. MicroRNA expression in response to murine myocardial infarction: miR-21 regulates fibroblast metalloprotease-2 via phosphatase and tensin homologue. Cardiovasc. Res. 2009, 82:21-29.
49. Liang H., Zhang C., Ban T., Liu Y., Mei L., Piao X., et al. A novel reciprocal loop between microRNA-21 and TGFbetaRIII is involved in cardiac fibrosis. Int. J. Biochem. Cell Biol. 2012, 44:2152-2160.
50. Liu G., Friggeri A., Yang Y., Milosevic J., Ding Q., Thannickal V.J., et al. miR-21 mediates fibrogenic activation of pulmonary fibroblasts and lung fibrosis. J. Exp. Med. 2010, 207:1589-1597.
51. Chau B.N., Xin C., Hartner J., Ren S., Castano A.P., Linn G., et al. MicroRNA-21 promotes fibrosis of the kidney by silencing metabolic pathways. Sci. Transl. Med. 2012, 4.
52. Zhang J., Jiao J., Cermelli S., Muir K., Jung K.H., Zou R., et al. miR-21 inhibition reduces liver fibrosis and prevents tumor development by inducing apoptosis of CD24+ progenitor cells. Cancer Res. 2015, 75:1859-1867.
53. Patrick D.M., Montgomery R.L., Qi X., Obad S., Kauppinen S., Hill J.A., et al. Stress-dependent cardiac remodeling occurs in the absence of microRNA-21 in mice. J. Clin. Invest. 2010, 120:3912-3916.
54. van Rooij E., Sutherland L.B., Thatcher J.E., DiMaio J.M., Naseem R.H., Marshall W.S., et al. Dysregulation of microRNAs after myocardial infarction reveals a role of miR-29 in cardiac fibrosis. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:13027-13032.
55. Abonnenc M., Nabeebaccus A.A., Mayr U., Barallobre-Barreiro J., Dong X., Cuello F., et al. Extracellular matrix secretion by cardiac fibroblasts: role of microRNA-29b and microRNA-30c. Circ. Res. 2013, 113:1138-1147.
56. Zhang Y., Huang X.R., Wei L.H., Chung A.C., Yu C.M., Lan H.Y. miR-29b as a therapeutic agent for angiotensin II-induced cardiac fibrosis by targeting TGF-beta/Smad3 signaling. Mol. Ther. 2014, 22. (974-85).
57. Hullinger T.G., Montgomery R.L., Seto A.G., Dickinson B.A., Semus H.M., Lynch J.M., et al. Inhibition of miR-15 protects against cardiac ischemic injury. Circ. Res. 2012, 110:71-81.
58. Tijsen A.J., van der Made I., van den Hoogenhof M.M., Wijnen W.J., van Deel E.D., de Groot N.E., et al. The microRNA-15 family inhibits the TGFbeta-pathway in the heart. Cardiovasc. Res. 2014, 104:61-71.
59. Pan Z., Sun X., Shan H., Wang N., Wang J., Ren J., et al. MicroRNA-101 inhibited postinfarct cardiac fibrosis and improved left ventricular compliance via the FBJ osteosarcoma oncogene/transforming growth factor-beta1 pathway. Circulation 2012, 126:840-850.
60. Zhao X., Wang K., Liao Y., Zeng Q., Li Y., Hu F., et al. MicroRNA-101a inhibits cardiac fibrosis induced by hypoxia via targeting TGFbetaRI on cardiac fibroblasts. Cell. Physiol. Biochem. 2015, 35:213-226.
61. Duisters R.F., Tijsen A.J., Schroen B., Leenders J.J., Lentink V., van der Made I., et al. miR-133 and miR-30 regulate connective tissue growth factor: implications for a role of microRNAs in myocardial matrix remodeling. Circ. Res. 2009, 104:170-178. (6p following 8).
62. Care A., Catalucci D., Felicetti F., Bonci D., Addario A., Gallo P., et al. MicroRNA-133 controls cardiac hypertrophy. Nat. Med. 2007, 13:613-618.
63. Matkovich S.J., Wang W., Tu Y., Eschenbacher W.H., Dorn L.E., Condorelli G., et al. MicroRNA-133a protects against myocardial fibrosis and modulates electrical repolarization without affecting hypertrophy in pressure-overloaded adult hearts. Circ. Res. 2010, 106:166-175.
64. Liu N., Bezprozvannaya S., Williams A.H., Qi X., Richardson J.A., Bassel-Duby R., et al. microRNA-133a regulates cardiomyocyte proliferation and suppresses smooth muscle gene expression in the heart. Genes Dev. 2008, 22:3242-3254.
65. Ucar A., Gupta S.K., Fiedler J., Erikci E., Kardasinski M., Batkai S., et al. The miRNA-212/132 family regulates both cardiac hypertrophy and cardiomyocyte autophagy. Nat. Commun. 2012, 3:1078.
66. van Rooij E., Sutherland L.B., Qi X., Richardson J.A., Hill J., Olson E.N. Control of stress-dependent cardiac growth and gene expression by a microRNA. Science 2007, 316:575-579.
67. Montgomery R.L., Hullinger T.G., Semus H.M., Dickinson B.A., Seto A.G., Lynch J.M., et al. Therapeutic inhibition of miR-208a improves cardiac function and survival during heart failure. Circulation 2011, 124:1537-1547.
68. Bernardo B.C., Gao X.M., Winbanks C.E., Boey E.J., Tham Y.K., Kiriazis H., et al. Therapeutic inhibition of the miR-34 family attenuates pathological cardiac remodeling and improves heart function. Proc. Natl. Acad. Sci. U. S. A. 2012, 109:17615-17620.
69. Huang Y., Qi Y., Du J.Q., Zhang D.F. MicroRNA-34a regulates cardiac fibrosis after myocardial infarction by targeting Smad4. Expert Opin. Ther. Targets 2014, 18:1355-1365.
70. da Costa Martins P.A., Salic K., Gladka M.M., Armand A.S., Leptidis S., el Azzouzi H., et al. MicroRNA-199b targets the nuclear kinase Dyrk1a in an auto-amplification loop promoting calcineurin/NFAT signalling. Nat. Cell Biol. 2010, 12:1220-1227.
71. Wang K., Liu F., Zhou L.Y., Long B., Yuan S.M., Wang Y., et al. The long noncoding RNA CHRF regulates cardiac hypertrophy by targeting miR-489. Circ. Res. 2014, 114:1377-1388.
72. Schonrock N., Harvey R.P., Mattick J.S. Long noncoding RNAs in cardiac development and pathophysiology. Circ. Res. 2012, 111:1349-1362.
73. Derrien T., Johnson R., Bussotti G., Tanzer A., Djebali S., Tilgner H., et al. The GENCODE v7 catalog of human long noncoding RNAs: analysis of their gene structure, evolution, and expression. Genome Res. 2012, 22:1775-1789.
74. van Heesch S., van Iterson M., Jacobi J., Boymans S., Essers P.B., de Bruijn E., et al. Extensive localization of long noncoding RNAs to the cytosol and mono- and polyribosomal complexes. Genome Biol. 2014, 15:R6.
75. Fatica A., Bozzoni I. Long non-coding RNAs: new players in cell differentiation and development. Nat. Rev. Genet. 2014, 15:7-21.
76. Wang K.C., Yang Y.W., Liu B., Sanyal A., Corces-Zimmerman R., Chen Y., et al. A long noncoding RNA maintains active chromatin to coordinate homeotic gene expression. Nature 2011, 472:120-124.
77. Li X., Wu Z., Fu X., Han W. LncRNAs: insights into their function and mechanics in underlying disorders. Mutat. Res. Rev. Mutat. Res. 2014, 762:1-21.
78. Salmena L., Poliseno L., Tay Y., Kats L., Pandolfi P.P. A ceRNA hypothesis: the Rosetta Stone of a hidden RNA language?. Cell 2011, 146:353-358.
79. Maass P.G., Luft F.C., Bahring S. Long non-coding RNA in health and disease. J. Mol. Med. (Berl.) 2014, 92:337-346.
80. Johnsson P., Lipovich L., Grander D., Morris K.V. Evolutionary conservation of long non-coding RNAs; sequence, structure, function. Biochim. Biophys. Acta 1840, 2014:1063-1071.
81. Anderson D.M., Anderson K.M., Chang C.L., Makarewich C.A., Nelson B.R., McAnally J.R., et al. A micropeptide encoded by a putative long noncoding RNA regulates muscle performance. Cell 2015, 160:595-606.
82. Han P., Li W., Lin C.H., Yang J., Shang C., Nurnberg S.T., et al. A long noncoding RNA protects the heart from pathological hypertrophy. Nature 2014, 514:102-106.
83. Wang K., Long B., Zhou L.Y., Liu F., Zhou Q.Y., Liu C.Y., et al. CARL lncRNA inhibits anoxia-induced mitochondrial fission and apoptosis in cardiomyocytes by impairing miR-539-dependent PHB2 downregulation. Nat. Commun. 2014, 5:3596.
84. Michalik K.M., You X., Manavski Y., Doddaballapur A., Zornig M., Braun T., et al. Long noncoding RNA MALAT1 regulates endothelial cell function and vessel growth. Circ. Res. 2014, 114:1389-1397.
85. Jiang X.Y., Ning Q.L. Expression profiling of long noncoding RNAs and the dynamic changes of lncRNA-NR024118 and Cdkn1c in angiotensin II-treated cardiac fibroblasts. Int. J. Clin. Exp. Pathol. 2014, 7:1325-1336.
86. Jiang X., Zhang F., Ning Q. Losartan reverses the down-expression of long noncoding RNA-NR024118 and Cdkn1c induced by angiotensin II in adult rat cardiac fibroblasts. Pathol. Biol. (Paris) 2015, 63:122-125.
87. Zhou Q., Chung A.C., Huang X.R., Dong Y., Yu X., Lan H.Y. Identification of novel long noncoding RNAs associated with TGF-beta/Smad3-mediated renal inflammation and fibrosis by RNA sequencing. Am. J. Pathol. 2014, 184:409-417.
88. Zhang X., Zhou Y., Mehta K.R., Danila D.C., Scolavino S., Johnson S.R., et al. A pituitary-derived MEG3 isoform functions as a growth suppressor in tumor cells. J. Clin. Endocrinol. Metab. 2003, 88:5119-5126.
89. He Y., Wu Y.T., Huang C., Meng X.M., Ma T.T., Wu B.M., et al. Inhibitory effects of long noncoding RNA MEG3 on hepatic stellate cells activation and liver fibrogenesis. Biochim. Biophys. Acta 1842, 2014:2204-2215.
90. Mondal T., Subhash S., Vaid R., Enroth S., Uday S., Reinius B., et al. MEG3 long noncoding RNA regulates the TGF-beta pathway genes through formation of RNA-DNA triplex structures. Nat. Commun. 2015, 6:7743.
91. Krutzfeldt J., Rajewsky N., Braich R., Rajeev K.G., Tuschl T., Manoharan M., et al. Silencing of microRNAs in vivo with 'antagomirs'. Nature 2005, 438:685-689.
92. Karakikes I., Chaanine A.H., Kang S., Mukete B.N., Jeong D., Zhang S., et al. Therapeutic cardiac-targeted delivery of miR-1 reverses pressure overload-induced cardiac hypertrophy and attenuates pathological remodeling. J. Am. Heart Assoc. 2013, 2.
93. Lorenzen J.M., Schauerte C., Hubner A., Kolling M., Martino F., Scherf K., et al. Osteopontin is indispensible for AP1-mediated angiotensin II-related miR-21 transcription during cardiac fibrosis. Eur. Heart J. 2015, 36:2184-2196.
94. Wang B.W., Wu G.J., Cheng W.P., Shyu K.G. MicroRNA-208a increases myocardial fibrosis via endoglin in volume overloading heart. PLoS One 2014, 9.
95. Yu F., Zheng J., Mao Y., Dong P., Lu Z., Li G., et al. Long Non-coding RNA growth arrest-specific transcript 5 (GAS5) inhibits liver fibrogenesis through a mechanism of competing endogenous RNA. J. Biol. Chem. 2015.
96. Cao G., Zhang J., Wang M., Song X., Liu W., Mao C., et al. Differential expression of long non-coding RNAs in bleomycin-induced lung fibrosis. Int. J. Mol. Med. 2013, 32:355-364.
97. Song X., Cao G., Jing L., Lin S., Wang X., Zhang J., et al. Analysing the relationship between lncRNA and protein-coding gene and the role of lncRNA as ceRNA in pulmonary fibrosis. J. Cell. Mol. Med. 2014, 18:991-1003.